跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
徐 之昇
副教授
,
國際生技醫療管理博士學位學程
合聘副教授
,
大數據科技及管理研究所
副教授
,
臺北醫學大學人工智慧醫療研究中心
https://orcid.org/0000-0003-2997-2404
電子郵件
jasonhsu
tmu.edu
tw
h-index
525
引文
14
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2013
2025
每年研究成果
概覽
指紋
網路
專案
(9)
研究成果
(69)
資料集
(2)
類似的個人檔案
(6)
指紋
查看啟用 Jason C. Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
31%
All Cause Mortality
30%
Anticarcinogen
21%
Antidiabetic Agent
46%
Bisphosphonic Acid Derivative
18%
Botulinum Toxin
12%
Brain Ischemia
14%
Breast Cancer
70%
Calcium Channel Blocker
12%
Cancer Survival
25%
Cardiovascular Disease
15%
Chemotherapy
28%
Clinical Research
41%
Cohort Study
43%
Combination Therapy
15%
Community Pharmacy
12%
Comorbidity
25%
Denosumab
13%
Disease
38%
Drug Utilization
26%
Epidermal Growth Factor Receptor
18%
Erlotinib
21%
Febrile Neutropenia
29%
Fragility Fracture
15%
Gefitinib
17%
Granulocyte Colony Stimulating Factor
25%
Health Status
14%
Heart Infarction
12%
Hip Fracture
38%
Immune Checkpoint Inhibitor
25%
Infection
13%
Injury Severity
12%
Lung Cancer
16%
Malignant Neoplasm
100%
Non Small Cell Lung Cancer
46%
Observational Study
44%
Oral Antidiabetic Agent
14%
Overall Survival
17%
Pioglitazone
18%
Population Study
14%
Prescription Medication
12%
Prevalence
14%
Progression Free Survival
14%
Proton Pump Inhibitor
12%
Retrospective Study
22%
Rosiglitazone
18%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Spine Fracture
39%
Thiazolidinedione
25%
Zoledronic Acid
17%
Medicine and Dentistry
Adverse Event
15%
Anticarcinogen
15%
Antidiabetic Agent
37%
Attitude
12%
Biological Therapy
12%
Brain Ischemia
12%
Breast Cancer
45%
Cancer Diagnosis
20%
Cancer Mortality
12%
Cancer Registry
14%
Cancer Therapy
40%
Case-Control Study
12%
Clinical Research
34%
COVID-19
25%
Degenerative Disease
12%
Diabetes
23%
Diabetes Mellitus
14%
Disease
30%
Drug Therapy
45%
Drug-Eluting Stent
12%
Electronic Health Record
13%
Endoscopy
16%
Epidermal Growth Factor Receptor
18%
Erlotinib
25%
Gefitinib
25%
Health Care Cost
48%
Hepatocellular Carcinoma
12%
Hypersalivation
12%
Implant
12%
Infection
13%
Logistic Regression Analysis
19%
Lung Cancer
14%
Lung Cancer Survival
25%
Malignant Neoplasm
30%
Maturity Onset Diabetes of the Young
16%
Meta-Analysis
25%
Microwave Thermotherapy
12%
Network Meta-Analysis
25%
Non Small Cell Lung Cancer
25%
Odds Ratio
17%
Osteoporosis
12%
Particle Therapy
12%
Patient Care
14%
Radiation Therapy
12%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Spastic Diplegia
12%
Systematic Review
50%
Targeted Therapy
50%
Time Series Analysis
41%
Tyrosine-Kinase Inhibitor
12%
Nursing and Health Professions
Acute Heart Infarction
12%
Adverse Event
12%
Area under the Curve
20%
Artificial Neural Network
9%
Bare Metal Stent
12%
Botulinum Toxin
12%
Botulinum Toxin A
9%
Brain Ischemia
12%
Breast Cancer
52%
Cancer Diagnosis
14%
Cancer Screening
12%
Cancer Survival
12%
Cancer Therapy
26%
Cerebral Palsy
12%
Cohort Analysis
13%
Comorbidity
8%
Drug Eluting Stent
12%
Drug Therapy
20%
Emergency Ward
7%
Empathy
12%
Erlotinib
8%
Febrile Neutropenia
16%
Gefitinib
10%
Granulocyte Colony Stimulating Factor
12%
Health Care Facility
12%
Health Center
10%
Heart Infarction
12%
Hip Fracture
12%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
12%
Hypersalivation
12%
Infertility Therapy
12%
Logistic Regression Analysis
11%
Meta Analysis
12%
National Health Insurance
20%
Non Small Cell Lung Cancer
12%
Patient Care
12%
Physician
14%
Predictive Value
10%
Private Hospital
10%
Public Hospital
12%
Receiver Operating Characteristic
18%
Reimbursement
13%
Social Media
12%
Sodium Glucose Cotransporter 2 Inhibitor
12%
Spine Fracture
12%
Statin (Protein)
12%
Systematic Review
12%
Teleconsultation
12%
Thorax Pain
12%
Time Series Analysis
13%
